PHILADELPHIA, PA — Proscia has launched the fifth generation of its Concentriq digital pathology platform, introducing a new artificial intelligence architecture designed to automate workflow-intensive tasks for pathologists and drug developers as healthcare organizations increasingly adopt AI-driven diagnostic and research tools.
The release targets a growing operational challenge in pathology, where more than half of pathologists report insufficient time to manage workloads while pharmaceutical companies face pressure to accelerate biomarker discovery and precision medicine programs.
Proscia said the platform’s redesigned architecture integrates vision, language and multimodal AI models capable of analyzing images, metadata and clinical context within a single environment. The company said the system was developed to support diagnostic case review, laboratory operations and drug development workflows.
The Philadelphia-based company serves diagnostic laboratories that collectively manage approximately 12 million patient cases annually and counts 16 of the world’s 20 largest pharmaceutical companies among its customers.
“AI transformation succeeds or fails in the projects and programs that deliver it,” Chief Technology Officer Coleman Stavish said. “Years of learning from our customers has helped us understand where complexity slows them down and where judgment gets crowded out by process.”
For pathology laboratories, the platform is designed to accelerate case review by combining image analysis, workflow automation and contextual clinical information within a single interface. The company also said AI tools can help laboratories balance workloads, recommend testing protocols and identify operational bottlenecks.
Proscia said the platform’s storage management capabilities can reduce long-term storage costs by more than 50% while maintaining access to case data used for quality review, artificial intelligence validation and pharmaceutical collaborations.
The company is also positioning the platform as a tool for pharmaceutical research and development, particularly in biomarker discovery and clinical trial operations.
According to Proscia, scientists can use the system to search across pathology, clinical and translational datasets, while AI agents assist with analysis design and biomarker evaluation. The platform also supports biomarker-driven clinical trials by helping identify eligible patients and standardize evaluation criteria across study sites.
“We use Concentriq to run anatomic pathology testing for drug development across multiple laboratories on three continents,” Dr. John Cochran, vice president and chief medical officer at IQVIA Laboratories, said. He described the new platform as applying AI to “elevating pathologists and scientists and growing pathology’s role in precision medicine.”
The launch follows increasing investment across healthcare and life sciences in AI-powered diagnostic and research tools as organizations seek to address workforce shortages, rising case volumes and growing demand for precision medicine.
Proscia said the fifth-generation platform is available immediately through an early-access program for existing customers. Initial deployments are scheduled to begin this month with select laboratories and biopharmaceutical companies, with broader availability planned later this year.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.